CLAIMS

1. A pharmaceutical composition that is formulated for topical application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is ~~between 9: 1 and 18:~~ from 11:1 to 16:1.

2. The composition according to claim 1 for use as a medicament for treating and/or inhibiting the development or progression of cervical cancers and benign proliferative disorders of the cervix.

3. The composition according to claim ~~2 wherein the composition comprises an effective amount of lopinavir and ritonavir for treating a Human Papilloma Virus (HPV) infection with or without attendant abnormal pathology.~~

~~4. The composition according to any preceding claim for use as a medicament for treating and/or inhibiting the development of early stage neoplasias.~~

~~5. The composition according to any preceding claim for use as a medicament for treating or preventing the development of HPV related cervical neoplasias.~~

~~6. The composition according to any preceding claim wherein lopinavir and ritonavir are included in a weight ratio (w/w) of between 10: 1 and 16: 1.~~

~~7. The composition according to claim 6 wherein lopinavir and ritonavir are included in a weight ratio of about 11 : 1 – 16: 1.~~

~~8. The composition according to claim 7~~1 wherein lopinavir and ritonavir are included in a weight ratio of about 12:1.

~~9~~4. The composition according to ~~any preceding~~ claim 1 wherein the composition is formulated as an ointment, gel, paste, cream, lotion, ovule, soft capsule, suppository, pessary, or any combination thereof.

~~10~~5. The composition according to ~~any preceding~~ claim 1 wherein the pharmaceutically acceptable vehicle is an ointment.

~~11~~6. The composition according to claim ~~10~~5 wherein the composition is an anhydrous composition for topical application comprising:

(a) Lopinavir and ritonavir in a weight ratio ~~of between 9: 1 and 18:~~ from 11:1 to 16:1; and

(b) a hydrophilic muco-adhesive agent;

wherein upon topical administration of the anhydrous composition to a site of application the ~~anhydrous composition transforms into a muco-adhesive composition.~~

~~12. The~~anhydrous composition transforms into a muco-adhesive composition.

7. The composition according to claim ~~11~~6 wherein the muco-adhesive agent is hydroxypropylmethylcellulose.

~~13~~8. The composition according to claim ~~11 or 12~~6 comprising ritonavir, lopinavir, hydroxypropylmethylcellulose, oleic acid, stearic acid; and butylated hydroxytoluene.

~~14~~9. The composition according to claim ~~10~~5 wherein the composition comprises:

(a) an unsaturated free fatty acid;

(b) a stiffening agent; and

(c) lopinavir and ritonavir in a weight ratio ~~of between 9: 1 and 18:~~ from 11:1 to 16:1;

wherein the unsaturated free fatty acid is present at a level of at least 20% by weight of the total pharmaceutical composition weight and wherein the pharmaceutical composition is a semi-solid at room temperature.

~~15. A method of~~10. Use of a therapeutically effective amount of a pharmaceutical composition according to claim 1, in the manufacture of a medicament for treating and/or inhibiting the development or progression of cervical cancers and benign proliferative disorders of the cervix in a subject in need of such treatment or inhibition ~~comprising administering a therapeutically effective amount of a pharmaceutical composition according to any of claims 1 - 14~~, wherein the medicament is to be administered to said subject.

~~16~~11. The ~~method~~use according to claim ~~15~~10 wherein the cancer or disorder is caused or induced by a human papilloma virus (HPV).

~~17. A method of treating a patient having an HPV related dysplasia of the cervix comprising administering intravaginally to said patient~~

12. Use of a therapeutically effective dose of a pharmaceutical composition according to ~~any one of claims~~claim 1 ~~- 14~~, in the manufacture of a medicament for treating a patient having an HPV related dysplasia of the cervix, wherein the medicament is to be administeredintravaginally to said patient.

~~18~~13. The ~~method~~use of claim ~~17~~12, wherein the pharmaceutical composition reduces the severity of the HPV related dysplasia.

~~19~~14. The ~~method~~use of claim ~~18~~13, wherein the severity of the HPV related dysplasia is reduced from CIN3 to CIN2, from CIN3 to CIN1, from CIN3 to HPV negative, from CIN2 to CIN1, from CIN2 to HPV negative, or from CIN1 to HPV negative.

~~20~~15. The ~~method~~use of ~~any one of claims 16-19~~claim 11, wherein the composition induces apoptosis of HPV infected cells.

~~21~~16. The ~~method~~use of ~~any one of claims 15-20~~claim 10, wherein the patient has a cervical cytology of high grade squamous intraepithelial lesion (HSIL), atypical squamous cells of undetermined significance (ASCUS), or low grade squamous intraepithelial lesion (LSIL).

~~22~~17. The ~~method~~use of claim ~~21~~16, wherein the composition reduces the cervical cytology from HSIL to a normal cytology, from HSIL to ACSUS, from HSIL to LSIL, from ACSUS to a normal cytology, or from LSIL to a normal cytology.

18. Use of an effective amount of a pharmaceutical composition according to claim 1, in the manufacture of a medicament for treating a Human Papilloma Virus (HPV) infection with or without attendant abnormal pathology.